New drug combo aims to outsmart resistant lung cancer
NCT ID NCT07322783
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether adding savolitinib to osimertinib can help people with a certain type of advanced lung cancer (EGFR-mutated NSCLC) that has become resistant to osimertinib. The study enrolls 60 adults whose tumors have low levels of MET amplification. Participants take both drugs daily until the disease worsens or side effects become too severe. The main goal is to see how many patients' tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Osimertinib and savolitinib (two cancer drugs taken as pills)
What this could lead to
If it works, this could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to standard therapy.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply widely. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qingdao Central Hospital
RECRUITINGQingdao, 266042, China
Contact Phone: •••-•••-•••• Email: •••••@•••••